MetaSafe AB has been acquired by Admescope Ltd, a Finnish CRO specialised in pre-clinical ADME-Tox research.

The acquisition creates a unique service offering, truly adding value to both Admescope’s and MetaSafe’s customers. MetaSafe’s top-notch knowledge in safety-related metabolism studies during drug development will further strengthen Admescope’s drug metabolism services to clinical phase projects.

MetaSafe becomes an integrated part of Admescope and will continue to operate the business in Södertälje, Sweden with the existing team. In addition to the new services, the acquisition also gives Admescope another location for high-quality laboratories.

We are very excited about the acquisition and are looking forward to serving our customers with the further strengthened service offering.